Is CGEM or QTTB more profitable?

Q32 Bio's return on equity of 50.17% beat Cullinan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cullinan Therapeutics N/A -52.89% -48.18% Q32 Bio N/A 50.17% 29.49%

Does the media refer more to CGEM or QTTB?

In the previous week, Q32 Bio had 4 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 10 mentions for Q32 Bio and 6 mentions for Cullinan Therapeutics. Q32 Bio's average media sentiment score of 1.15 beat Cullinan Therapeutics' score of 0.16 indicating that Q32 Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Q32 Bio 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is QTTB or FBRX more profitable?

Q32 Bio's return on equity of 50.17% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Q32 Bio N/A 50.17% 29.49% Forte Biosciences N/A -106.17% -85.50%

Does the media prefer QTTB or FBRX?

In the previous week, Q32 Bio had 3 more articles in the media than Forte Biosciences. MarketBeat recorded 10 mentions for Q32 Bio and 7 mentions for Forte Biosciences. Q32 Bio's average media sentiment score of 1.15 beat Forte Biosciences' score of 0.64 indicating that Q32 Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Q32 Bio 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Forte Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is QTTB or JBIO more profitable?

Q32 Bio's return on equity of 50.17% beat Jade Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Q32 Bio N/A 50.17% 29.49% Jade Biosciences N/A -51.34% -47.32%

Does the media prefer QTTB or JBIO?

In the previous week, Q32 Bio had 6 more articles in the media than Jade Biosciences. MarketBeat recorded 10 mentions for Q32 Bio and 4 mentions for Jade Biosciences. Q32 Bio's average media sentiment score of 1.15 beat Jade Biosciences' score of 0.89 indicating that Q32 Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Q32 Bio 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jade Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate QTTB or CVAC?

Q32 Bio presently has a consensus target price of $30.00, indicating a potential upside of 92.31%. Given Q32 Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Q32 Bio is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Q32 Bio 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, QTTB or CVAC?

CureVac has higher revenue and earnings than Q32 Bio. Q32 Bio is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Q32 Bio $53.74M 4.92 $29.82M $3.00 5.20 CureVac $70.74M 14.78 $175.50M $0.72 6.47

Is QTTB or CVAC more profitable?

CureVac has a net margin of 199.92% compared to Q32 Bio's net margin of 0.00%. Q32 Bio's return on equity of 50.17% beat CureVac's return on equity. Company Net Margins Return on Equity Return on Assets Q32 Bio N/A 50.17% 29.49% CureVac 199.92% -23.03% -19.09%

Is QTTB or OLMA more profitable?

Q32 Bio's return on equity of 50.17% beat Olema Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Q32 Bio N/A 50.17% 29.49% Olema Pharmaceuticals N/A -46.00% -41.22%

Does the media refer more to QTTB or OLMA?

In the previous week, Q32 Bio had 4 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 10 mentions for Q32 Bio and 6 mentions for Olema Pharmaceuticals. Q32 Bio's average media sentiment score of 1.15 beat Olema Pharmaceuticals' score of 0.58 indicating that Q32 Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Q32 Bio 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Olema Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Q32 Bio (QTTB) Competitors

$15.60 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$15.79 +0.19 (+1.19%)

As of 08/7/2026 07:49 PM Eastern

Compare

QTTB vs. CGEM, FBRX, JBIO, CVAC, and OLMA

Should you buy Q32 Bio stock or one of its competitors? MarketBeat compares Q32 Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Q32 Bio include Cullinan Therapeutics (CGEM), Forte Biosciences (FBRX), Jade Biosciences (JBIO), CureVac (CVAC), and Olema Pharmaceuticals (OLMA). These companies are all part of the "biotechnology" industry.

How does Q32 Bio compare to Cullinan Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Q32 Bio (NASDAQ:QTTB) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

In the previous week, Q32 Bio had 4 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 10 mentions for Q32 Bio and 6 mentions for Cullinan Therapeutics. Q32 Bio's average media sentiment score of 1.15 beat Cullinan Therapeutics' score of 0.16 indicating that Q32 Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Q32 Bio	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Q32 Bio has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A
Q32 Bio	$53.74M	4.92	$29.82M	$3.00	5.20

86.3% of Cullinan Therapeutics shares are held by institutional investors. Comparatively, 31.3% of Q32 Bio shares are held by institutional investors. 8.6% of Cullinan Therapeutics shares are held by company insiders. Comparatively, 34.5% of Q32 Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cullinan Therapeutics currently has a consensus price target of $32.14, suggesting a potential upside of 81.29%. Q32 Bio has a consensus price target of $30.00, suggesting a potential upside of 92.31%. Given Q32 Bio's stronger consensus rating and higher probable upside, analysts plainly believe Q32 Bio is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Q32 Bio's return on equity of 50.17% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-52.89%	-48.18%
Q32 Bio	N/A	50.17%	29.49%

Cullinan Therapeutics has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market. Comparatively, Q32 Bio has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market.

Summary

Q32 Bio beats Cullinan Therapeutics on 12 of the 14 factors compared between the two stocks.

How does Q32 Bio compare to Forte Biosciences?

Q32 Bio (NASDAQ:QTTB) and Forte Biosciences (NASDAQ:FBRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Q32 Bio's return on equity of 50.17% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Q32 Bio	N/A	50.17%	29.49%
Forte Biosciences	N/A	-106.17%	-85.50%

Q32 Bio has higher revenue and earnings than Forte Biosciences. Forte Biosciences is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q32 Bio	$53.74M	4.92	$29.82M	$3.00	5.20
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A

31.3% of Q32 Bio shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 34.5% of Q32 Bio shares are owned by insiders. Comparatively, 4.4% of Forte Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Q32 Bio had 3 more articles in the media than Forte Biosciences. MarketBeat recorded 10 mentions for Q32 Bio and 7 mentions for Forte Biosciences. Q32 Bio's average media sentiment score of 1.15 beat Forte Biosciences' score of 0.64 indicating that Q32 Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Q32 Bio	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Forte Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Q32 Bio presently has a consensus price target of $30.00, indicating a potential upside of 92.31%. Forte Biosciences has a consensus price target of $72.50, indicating a potential downside of 5.59%. Given Q32 Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Q32 Bio is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Q32 Bio has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.6, suggesting that its stock price is 160% more volatile than the broader market.

Summary

Q32 Bio beats Forte Biosciences on 12 of the 14 factors compared between the two stocks.

How does Q32 Bio compare to Jade Biosciences?

Q32 Bio (NASDAQ:QTTB) and Jade Biosciences (NASDAQ:JBIO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

31.3% of Q32 Bio shares are owned by institutional investors. 34.5% of Q32 Bio shares are owned by company insiders. Comparatively, 23.1% of Jade Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Q32 Bio currently has a consensus target price of $30.00, indicating a potential upside of 92.31%. Jade Biosciences has a consensus target price of $51.57, indicating a potential upside of 134.84%. Given Jade Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Jade Biosciences is more favorable than Q32 Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Q32 Bio's return on equity of 50.17% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Q32 Bio	N/A	50.17%	29.49%
Jade Biosciences	N/A	-51.34%	-47.32%

Q32 Bio has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q32 Bio	$53.74M	4.92	$29.82M	$3.00	5.20
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A

In the previous week, Q32 Bio had 6 more articles in the media than Jade Biosciences. MarketBeat recorded 10 mentions for Q32 Bio and 4 mentions for Jade Biosciences. Q32 Bio's average media sentiment score of 1.15 beat Jade Biosciences' score of 0.89 indicating that Q32 Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Q32 Bio	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jade Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Q32 Bio has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market.

Summary

Q32 Bio beats Jade Biosciences on 10 of the 15 factors compared between the two stocks.

How does Q32 Bio compare to CureVac?

Q32 Bio (NASDAQ:QTTB) and CureVac (NASDAQ:CVAC) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

CureVac has a net margin of 199.92% compared to Q32 Bio's net margin of 0.00%. Q32 Bio's return on equity of 50.17% beat CureVac's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Q32 Bio	N/A	50.17%	29.49%
CureVac	199.92%	-23.03%	-19.09%

In the previous week, Q32 Bio had 10 more articles in the media than CureVac. MarketBeat recorded 10 mentions for Q32 Bio and 0 mentions for CureVac. Q32 Bio's average media sentiment score of 1.15 beat CureVac's score of 0.00 indicating that Q32 Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Q32 Bio	Positive
CureVac	Neutral

CureVac has higher revenue and earnings than Q32 Bio. Q32 Bio is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q32 Bio	$53.74M	4.92	$29.82M	$3.00	5.20
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

Q32 Bio presently has a consensus target price of $30.00, indicating a potential upside of 92.31%. Given Q32 Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Q32 Bio is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Q32 Bio has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

31.3% of Q32 Bio shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 34.5% of Q32 Bio shares are owned by company insiders. Comparatively, 2.2% of CureVac shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Q32 Bio beats CureVac on 10 of the 16 factors compared between the two stocks.

How does Q32 Bio compare to Olema Pharmaceuticals?

Q32 Bio (NASDAQ:QTTB) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Q32 Bio has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 2.03, suggesting that its stock price is 103% more volatile than the broader market.

Q32 Bio presently has a consensus target price of $30.00, suggesting a potential upside of 92.31%. Olema Pharmaceuticals has a consensus target price of $44.10, suggesting a potential upside of 265.98%. Given Olema Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Q32 Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Q32 Bio's return on equity of 50.17% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Q32 Bio	N/A	50.17%	29.49%
Olema Pharmaceuticals	N/A	-46.00%	-41.22%

In the previous week, Q32 Bio had 4 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 10 mentions for Q32 Bio and 6 mentions for Olema Pharmaceuticals. Q32 Bio's average media sentiment score of 1.15 beat Olema Pharmaceuticals' score of 0.58 indicating that Q32 Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Q32 Bio	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Olema Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

31.3% of Q32 Bio shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 34.5% of Q32 Bio shares are held by insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Q32 Bio has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q32 Bio	$53.74M	4.92	$29.82M	$3.00	5.20
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A

Summary

Q32 Bio beats Olema Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Get Q32 Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QTTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QTTB vs. The Competition

Export

Metric	Q32 Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$264.58M	$3.69B	$7.00B	$12.99B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	5.20	9.02	270.59	25.05
Price / Sales	4.92	1,294.46	599.45	84.15
Price / Cash	10.29	44.95	28.89	37.44
Price / Book	4.57	17.61	11.21	6.43
Net Income	$29.82M	-$13.25M	$3.45B	$348.10M
7 Day Performance	2.90%	4.99%	3.41%	2.68%
1 Month Performance	39.16%	-2.13%	-0.71%	-0.83%
1 Year Performance	857.06%	61.28%	77.31%	23.97%

Q32 Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QTTB Q32 Bio	4.6704 of 5 stars	$15.60 flat	$30.00 +92.3%	+857.1%	$264.58M	$53.74M	5.20	39	Positive News Earnings Report Analyst Revision Gap Up
CGEM Cullinan Therapeutics	2.3919 of 5 stars	$17.55 +8.0%	$32.14 +83.2%	+142.9%	$1.08B	N/A	N/A	30	Earnings Report
FBRX Forte Biosciences	1.387 of 5 stars	$76.56 -0.1%	$72.50 -5.3%	+654.3%	$1.06B	N/A	N/A	5	Upcoming Earnings
JBIO Jade Biosciences	3.2251 of 5 stars	$21.35 +11.5%	$51.57 +141.6%	+193.2%	$1.05B	N/A	N/A	20	High Trading Volume
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QTTB) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Q32 Bio (QTTB) Competitors

QTTB vs. CGEM, FBRX, JBIO, CVAC, and OLMA

How does Q32 Bio compare to Cullinan Therapeutics?

Summary

How does Q32 Bio compare to Forte Biosciences?

Summary

How does Q32 Bio compare to Jade Biosciences?

Summary

How does Q32 Bio compare to CureVac?

Summary

How does Q32 Bio compare to Olema Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTTB vs. The Competition

Q32 Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Q32 Bio (QTTB) Competitors

QTTB vs. CGEM, FBRX, JBIO, CVAC, and OLMA

How does Q32 Bio compare to Cullinan Therapeutics?

Does the media refer more to CGEM or QTTB?

Which has stronger earnings & valuation, CGEM or QTTB?

Do insiders and institutionals believe in CGEM or QTTB?

Do analysts recommend CGEM or QTTB?

Is CGEM or QTTB more profitable?

Which has more risk & volatility, CGEM or QTTB?

Summary

How does Q32 Bio compare to Forte Biosciences?

Is QTTB or FBRX more profitable?

Which has preferable valuation and earnings, QTTB or FBRX?

Do institutionals & insiders believe in QTTB or FBRX?

Does the media prefer QTTB or FBRX?

Do analysts prefer QTTB or FBRX?

Which has more risk & volatility, QTTB or FBRX?

Summary

How does Q32 Bio compare to Jade Biosciences?

Do institutionals & insiders have more ownership in QTTB or JBIO?

Do analysts recommend QTTB or JBIO?

Is QTTB or JBIO more profitable?

Which has better valuation & earnings, QTTB or JBIO?

Does the media prefer QTTB or JBIO?

Which has more volatility & risk, QTTB or JBIO?

Summary

How does Q32 Bio compare to CureVac?

Is QTTB or CVAC more profitable?

Does the media prefer QTTB or CVAC?

Which has better valuation and earnings, QTTB or CVAC?

Do analysts rate QTTB or CVAC?

Which has more volatility & risk, QTTB or CVAC?

Do insiders and institutionals have more ownership in QTTB or CVAC?

Summary

How does Q32 Bio compare to Olema Pharmaceuticals?

Which has more volatility and risk, QTTB or OLMA?

Do analysts recommend QTTB or OLMA?

Is QTTB or OLMA more profitable?

Does the media refer more to QTTB or OLMA?

Do institutionals and insiders have more ownership in QTTB or OLMA?

Which has stronger earnings & valuation, QTTB or OLMA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTTB vs. The Competition

Q32 Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools